研究スタッフ

[公開日] 2020年3月11日 [最終更新日] 2023年8月30日

敬天愛人

佐藤 潤

医員

専門医・認定医資格など

日本内科学会 認定内科医、総合内科専門医
日本臨床腫瘍学会 がん薬物療法専門医
日本呼吸器学会 呼吸器専門医

抗がん剤の早期薬剤開発に尽力しております。

座右の銘 至誠天に通ず
出身地 東京都
趣味 読書・釣り・家庭菜園
将来の目標 医学の進歩と治験の推進を通して、本邦の発展に貢献すること。
患者さんへ一言 遠慮なく何でも、何度でもご質問ください。良い医療の礎はコミュニケーションだと考えております。

佐藤 潤の代表的な論文

  1. Jun Sato, Miyako Satouchi, Shoichi Itoh, Yusuke Okuma, Seiji Niho, Hidenori Mizugaki, Haruyasu Murakami, Yasuhito Fujisaka, Toshiyuki Kozuki, Kenichi Nakamura, Yukari Nagasaka, Mamiko Kawasaki, Tomoaki Yamada, Ryunosuke Machida, Aya Kuchiba, Yuichiro Ohe, Noboru Yamamoto, Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial.The Lancet. Oncology, 2020.21(6):843-850.
  2. Jun Sato, Shigehisa Kitano, Noriko Motoi, Yoshinori Ino, Noboru Yamamoto, Shunichi Watanabe, Yuichiro Ohe, Nobuyoshi Hiraoka, CD20+ tumor-infiltrating immune cells and CD204+ M2 macrophages are associated with prognosis in thymic carcinoma. Cancer science, 2020. 111(6):1921-1932.
  3. Jun Sato, Toshio Shimizu, Takafumi Koyama, Satoru Iwasa, Akihiko Shimomura, Shunsuke Kondo, Shigehisa Kitano, Kan Yonemori, Yutaka Fujiwara, Kenji Tamura, Takuya Suzuki, Takao Takase, Reiko Nagai, Kohei Yamaguchi, Taro Semba, Zi-Ming Zhao, Min Ren, Noboru Yamamoto, Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors. Clinical cancer research, 2022. 8(9):1783-1791.
  4. Jun Sato, Hidehito Horinouchi, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Yuichiro Ohe, Long-term survival without surgery in NSCLC patients with synchronous brain oligometastasis: systemic chemotherapy revisited. Journal of thoracic disease, 2018.10(3):1696-1702.
  5. Jun Sato, Akihiko Shimomura, Junpei Kawauchi, Juntaro Matsuzaki, Yusuke Yamamoto, Satoko Takizawa, Hiromi Sakamoto, Makoto Ohno, Yoshitaka Narita, Takahiro Ochiya, Kenji Tamura, Brain metastasis-related microRNAs in patients with advanced breast cancer. PloS one, 2019. 14(10):e0221538.
  6. Jun Sato, Tatsunori Shimoi, Akihiko Shimomura, Emi Noguchi, Makoto Kodaira, Mayu Yunokawa, Kan Yonemori, Chikako Shimizu, Yasuhiro Fujiwara, Masayuki Yoshida, Kenji Tamura, The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site. Internal medicine (Tokyo, Japan), 2019. 58(10):1423-1428.
  7. Jun Sato, Satoru Iwasa, Yoshitaka Honma, Atsuo Takashima, Natsuko Okita, Ken Kato, Tetsuya Hamaguchi, Yasuhide Yamada, Narikazu Boku, Impact of Oxaliplatin-Induced Neuropathy on Subsequent Paclitaxel for Advanced Gastric Cancer. Inernational Journal of clinical oncology. , 2020. 11: p. 526-537.
  8. Rumi Nishimura, Hiroto Ishiki, Jun Sato, Eriko Satomi, Dexamethasone for cancer-related dyspnoea.The Lancet. Oncology, 2022, 23(12):e525.
  9. Shinobu Uzu, Jun Sato, Rika Wakao, Takahiro Nonaka, Analysis and enhancement of risk management for ethnic differences in antineoplastic drugs in Japan. BMC health services research, 2022. 22(1):1292-1292.
  10. Toshio Shimizu, Yutaka Fujiwara, Kan Yonemori, Takafumi Koyama, Jun Sato, Kenji Tamura, Akihiko Shimomura, Hiroki Ikezawa, Maiko Nomoto, Keiji Furuuchi, Ryo Nakajima, Takuma Miura, Noboru Yamamoto, First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors.Clinical cancer research, 2021.27(14):3905-3915.

佐藤 潤 医師が治験責任医師である治験一覧(実施中のもの)

該当する治験はありません。